Serum omentin-1, vaspin, and apelin levels and central obesity in patients with nonalcoholic fatty liver disease
Abstract
Background: Omentin?1, vaspin, and apelin are novel adipokines which closely associate with obesity, nonalcoholic fatty liverdisease (NAFLD), and inflammation. The aim of this study was to investigate the circulating levels of omentin?1, vaspin, and apelin inNAFLD patients and to clarify their relationship with biochemical parameters, abdominal obesity, and high sensitive C?reactive protein.Materials and Methods: In a case–control study, serum levels of omentin?1, vaspin, and apelin were measured in 41 NAFLD patientsand 41 healthy volunteers. The study was performed in the outpatients’ clinic of Imam?Ali Hospital in Zahedan, Iran, during Februaryto July 2015. Fatty liver was confirmed by ultrasonography. The association of the adipokines with lipid profile and anthropometricparameters was assessed using multivariable linear regression models. In this model, those variables that showed P < 0.05 wereincluded in the study. Results: NAFLD patients presented a significantly higher apelin levels compared to the controls (P < 0.01),whereas serum omentin?1 and vaspin levels did not differ between two groups (both P > 0.05). Multiple regression analysis showedthat the serum levels of apelin and vaspin correlated positively with waist circumference (WC) (P < 0.01 and P < 0.05, respectively)and low?density lipoprotein (P < 0.05 and P < 0.01, respectively) while serum omentin?1 was inversely correlated with WC (P < 0.01)and positively corrected with high?density lipoprotein (P < 0.05). Conclusions: The findings showed that among the analyzedadipokines only apelin was different in patients with NAFLD when compared to controls. Considering the multivariate regressionanalysis, apelin seems be more suitable diagnostic marker in predicting of NAFLD and omentin might be considered as a protectivefactor in occurrence of NAFLD, particularly in those with central obesity.
Key words: Adipokines, apelin, central obesity, nonalcoholic fatty liver disease, omentin, vaspin